We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Mirati Therapeutics, MedImmune Partner

News   Aug 06, 2015

 
Mirati Therapeutics, MedImmune Partner
 
 
 

RELATED ARTICLES

Safety and Efficacy Results From CRISPR/Cas9 Human Clinical Trials Are Positive

News

CRISPR Therapeutics and Vertex Pharmaceuticals have announced their interim safety and efficacy results from the CTX001 CRISPR/Cas9 gene-editing human clinical trials - and they're promising.

READ MORE

A Milestone Is Reached For New Leukemia Drug

News

Cold Spring Harbor Laboratory scientists, with chemists and cancer biologists from Dana-Farber Cancer Institute (DFCI), have developed a new therapy that extended the survival of mice with acute myeloid leukemia.

READ MORE

Collaboration Aims To Improve Efficacy of Lung Cancer Drug

News

The University of Barcelona and Hospital ClĂ­nic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug used to treat lung cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE